Novartis (NVS) Gains FDA Orphan Status for Myasthenia Gravis Treatment

 Novartis (NVS) has received orphan drug designation from the U.S. Food and Drug Administration for its pharmaceutical product iptacopan. This designation is specifically for the treatment of myasthenia gravis, a chronic autoimmune neuromuscular disease. The FDA's orphan drug status is designed to encourage the development of medications for rare conditions, providing benefits such as tax credits and market exclusivity.

https://www.gurufocus.com/news/4078221/novartis-nvs-gains-fda-orphan-status-for-myasthenia-gravis-treatment